CD19-ReTARGTPR selectively redecorated the SEM CD19pos human B-ALL cell line and redirected the cytotoxic activity of anti-CMV CD8pos T cells towards these cells in both a dose-dependent (Figure 2A) and effector-to-target (E:T) ratio-dependent manner (Figure 2B). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.